Canadian generic drugmaker Apotex Inc. is planning an initial public offering on the Toronto Stock Exchange during the first six months of the year. The company aims to raise as much as C$1 billion ($730 million), according to sources familiar with the matter. This move would mark a significant entry into the public markets for a major pharmaceutical manufacturer.

The potential listing follows a period of consolidation and pressure in the generic drug sector. Apotex, a long-standing private company, is seeking capital to navigate competitive pricing and fund growth initiatives. An IPO of this size would be one of the largest Canadian offerings in recent times, testing investor appetite for established but capital-intensive pharmaceutical businesses.

Proceeds would provide Apotex with enhanced financial flexibility for acquisitions, research, and debt reduction. The deal’s success hinges on market conditions and valuations for healthcare stocks. For Toronto’s exchange, attracting such a sizable domestic issuer supports its goal of becoming a premier venue for resource and industrial listings.

Investors will scrutinize Apotex’s pipeline and profitability against larger global rivals. The final pricing and timing remain subject to market volatility and regulatory approvals.